The role of nemolizumab in the treatment of atopic dermatitis for the adult population

References

• Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi:10.3390/ijms22084130
   PubMed Web of Science ®Google Scholar
• Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi:10.2500/aap.2019.40.4202
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. doi:10.1038/s41573-021-00266-6
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590. doi:10.1016/j.jid.2018.08.028
   PubMed Web of Science ®Google Scholar
• Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. doi:10.1038/jid.2013.446
   PubMed Web of Science ®Google Scholar
• Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):437–453. doi:10.1080/14737167.2020.1819793
   PubMed Web of Science ®Google Scholar
• Butala S, Castelo-Soccio L, Seshadri R, et al. Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations. J Allergy Clin Immunol Pract. 2023;11(5):1361–1373. doi:10.1016/j.jaip.2023.03.011
   PubMedGoogle Scholar
• Oyama S, Kitamura H, Kuramochi T, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018;27(1):14–21. doi:10.1111/exd.13236
   PubMed Web of Science ®Google Scholar
• Orfali RL, Aoki V. Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis. Pharmaceutics. 2023;15(2):577. doi:10.3390/pharmaceutics15020577
   PubMed Web of Science ®Google Scholar
• Presented at American Academy of Dermatology Annual Meeting. Silverberg JI. Maintenance of efficacy and safety with nemolizumab at Week 48: results from two global phase III pivotal studies (ARCADIA 1 and ARCADIA 2) in patients with moderate-to-severe atopic dermatitis. San Diego, (CA). Abstract 56887. AAD; March 8–12, 2024.
   Google Scholar
• Gooderham MJ, Bissonnette R, Grewal P, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutaneous Med Surg. 2018;22(Suppl. 1):S10–S16. doi:10.1177/1203475418803628
   Google Scholar
• Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10–19. doi:10.1159/000245677
   PubMed Web of Science ®Google Scholar
• Fishbein AB, Silverberg JI, Wilson EJ, et al. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91–101. doi:10.1016/j.jaip.2019.06.044
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Jones EA. Assessment of the visual analogue score in the evaluation of the pruritus of cholestasis. J Clin Transl Hepatol. 2017;5(3):203–207. doi:10.14218/JCTH.2017.00001
   PubMedGoogle Scholar
• Puelles J, Fofana F, Rodriguez D, et al. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis. Br J Dermatol. 2022;186(2):285–294. doi:10.1111/bjd.20783
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023
   PubMed Web of Science ®Google Scholar
• Tier HL, Balogh EA, Bashyam AM, et al. Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review. Dermatol Ther (Heidelb). 2021;11(2):415–431. doi:10.1007/s13555-021-00500-4
   PubMed Web of Science ®Google Scholar
• Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009;8(1):40–43. doi:10.1111/j.1473-2165.2009.00422.x
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. doi:10.1016/j.anai.2017.10.039
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–1531. doi:10.1016/j.jaip.2017.08.005
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed. 2006;8(4):8.
   PubMedGoogle Scholar
• Bissonnette R, Pavel AB, Diaz A, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274–1289. doi:10.1016/j.jaci.2019.06.047
   PubMed Web of Science ®Google Scholar
• Miyano K, Tsunemi Y. Current treatments for atopic dermatitis in Japan. J. Dermatol. 2021;48(2):140–151. doi:10.1111/1346-8138.15730
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi:10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus. Dermatol Ther (Heidelb). 2024;14(4):919–932. doi:10.1007/s13555-024-01135-x
   PubMed Web of Science ®Google Scholar
• Shah N, Alhusayen R, Walsh S, et al. Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. J Cutan Med Surg. 2018;22(5):484–487. doi:10.1177/1203475418781336
   PubMed Web of Science ®Google Scholar
• Darsow U, Wollenberg A, Simon D, et al. Difficult to control atopic dermatitis. World Allergy Organ J. 2013;6(1):6. doi:10.1186/1939-4551-6-6
   PubMedGoogle Scholar
• Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23. doi:10.1007/s13555-016-0170-1
   PubMed Web of Science ®Google Scholar
• Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590–598.
   PubMedGoogle Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Akhavan A, Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg. 2008;27(2):151–155. doi:10.1016/j.sder.2008.04.004
   PubMed Web of Science ®Google Scholar
• Szöllősi AG, Oláh A, Lisztes E, et al. Pruritus: a sensory symptom generated in cutaneous immuno-neuronal crosstalk [Review]. Front Pharmacol. 2022;13:745658. doi:10.3389/fphar.2022.745658
   PubMed Web of Science ®Google Scholar
• Keam SJ. Nemolizumab: first approval. Drugs. 2022;82(10):1143–1150. doi:10.1007/s40265-022-01741-z
   PubMed Web of Science ®Google Scholar
• Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29–36. doi:10.1111/all.13239
   PubMed Web of Science ®Google Scholar
• Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8:638325. doi:10.3389/fmed.2021.638325
   PubMed Web of Science ®Google Scholar
• Serra-Baldrich E, Santamaría-Babí LF, Francisco Silvestre J. Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis. Actas Dermosifiliogr. 2022;113(7):674–684. doi:10.1016/j.ad.2021.12.014
   PubMed Web of Science ®Google Scholar
• Meng J, Wang J, Buddenkotte J, et al. Role of SNAREs in atopic dermatitis-related cytokine secretion and skin-nerve communication. J Investigat Dermatol. 2019;139(11):2324–2333. doi:10.1016/j.jid.2019.04.017
   PubMed Web of Science ®Google Scholar
• Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: the “itchy” cytokine in inflammation and therapy. Allergy. 2021;76(10):2982–2997. doi:10.1111/all.14791
   PubMed Web of Science ®Google Scholar
• Arai I, Saito S. Interleukin-31 receptor a expression in the dorsal root ganglion of mice with atopic dermatitis. Int J Mol Sci. 2023;24(2):1047. doi:10.3390/ijms24021047
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi:10.2165/11531280-000000000-00000
   PubMed Web of Science ®Google Scholar
• Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174(2):296–304. doi:10.1111/bjd.14207
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182. doi:10.1016/j.jaci.2019.08.013
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835. doi:10.1056/NEJMoa1606490
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121–1130.e7. doi:10.1016/j.jaci.2018.03.018
   PubMed Web of Science ®Google Scholar
• Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141–150. doi:10.1056/NEJMoa1917006
   PubMed Web of Science ®Google Scholar
• Kabashima K, Matsumura T, Komazaki H, et al. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2022;186(4):642–651. doi:10.1111/bjd.20873
   PubMed Web of Science ®Google Scholar
• Galderma R&D. NCT03989349, Phase 3 clinical trial. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis.
   Google Scholar
• Liang J, Hu F, Dan M, et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. 2022;13:825312. doi:10.3389/fimmu.2022.825312
   PubMed Web of Science ®Google Scholar
• Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706–716. doi:10.1056/NEJMoa1908316
   PubMed Web of Science ®Google Scholar
• Xiao X, Lin L, Zhu C, et al. Efficacy and safety of nemolizumab for treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Investig Allergol Clin Immunol. 2021;31(2):190–192. doi:10.18176/jiaci.0672
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579–1589. doi:10.1056/NEJMoa2301333
   PubMed Web of Science ®Google Scholar
• Smith T. Biologics License Application for Nemolizumab Accepted by FDA for Prurigo Nodularis, Atopic Dermatitis. HCP Live 2024. https://www.hcplive.com/view/biologics-license-application-for-nemolizumab-accepted-by-fda-for-prurigo-nodularis-atopic-dermatitis
   Google Scholar
• Galderma R&D. NCT039899206 Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. September 26, 2023.
   Google Scholar
• Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(2):e239–242. doi:10.1111/j.1468-3083.2012.04578.x
   PubMed Web of Science ®Google Scholar